United States

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

22 Mar 2017
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Pfizer completes acquisition of small molecule anti-infective business from AstraZeneca
Friday, 23 Dec 2016 02:05am EST 

Pfizer Inc : Says completed acquisition of development rights to Astrazeneca's late-stage anti-infective business, primarily outside united states .Pfizer completes acquisition of small molecule anti-infective business from Astrazeneca.  Full Article

AstraZeneca completes sale of antibiotics business to Pfizer
Friday, 23 Dec 2016 02:00am EST 

AstraZeneca Plc : AZ completes sale of antibiotics business . Has completed agreement with Pfizer Inc for sale of commercialisation and development rights to its late-stage small molecule antibiotics business . AstraZeneca has received a payment of $550 million for commercialisation and development rights to late-stage antibiotics business in all markets where AstraZeneca holds rights . Pfizer will pay a further $175 mln in January 2019, up to $250 mln in commercial, manufacturing and regulatory milestones . Pfizer will pay up to $600 mln in sales-related payments as well as recurring, double-digit royalties .$550 mln upfront and $175 mln unconditional payment will both be booked in Q4 of 2016, net of a product intangible.  Full Article

Knight Therapeutics announces exclusive license agreement with AstraZeneca
Thursday, 15 Dec 2016 07:30am EST 

Knight Therapeutics Inc : The financial terms of agreement were not disclosed . Knight therapeutics- as per agreement, co will be responsible for all commercial, regulatory, certain supply chain activities for movantik in canada, israel . Movantik is currently under regulatory review in israel and, when approved, will be marketed under name moventig .Press release - knight therapeutics announces exclusive license agreement with astrazeneca for movantik/moventig(r) in canada and israel.  Full Article

AstraZeneca CEO: drug price pressure won't go away under Trump
Thursday, 10 Nov 2016 05:04am EST 

Astrazeneca executives comment to reporters after Q3 results: R&D executive says overall survival data from Mystic lung cancer trial expected in 2018, PFS data seen first half 2017 . CEO says U.S. price pressure won't go away with Trump presidency . CEO says hopes any replacement to Obamacare will promote innovation in medicine . CEO says confident of resuming enrolment in head and neck cancer drug trials after pause due to bleeding cases . CFO says Saudi Arabia healthcare cuts hurt Symbicort in Q3 because company no.1 in respiratory medicine in country . CEO says expects return to growth in second half of 2017, no drug patent expiries 2018-24 Further company coverage: [AZN.L] (Reporting by UK bureau) ((uk.online@reuters.com;)).  Full Article

AstraZeneca says Lynparza late-stage study succeeds
Wednesday, 26 Oct 2016 02:00am EDT 

AstraZeneca Plc : AstraZeneca plc - positive results in AstraZeneca Lynparza trial . Lynparza phase III SOLO-2 trial shows significant progression-free survival benefit . Initial findings show safety profile with Lynparza tablets was consistent with previous studies . Results from trial demonstrate a clinically-meaningful and statistically-significant improvement of progression-free survival .Median PFS in Lynparza arm of SOLO-2 substantially exceeded that observed in phase II maintenance study in patients with platinum-sensitive relapsed ovarian cancer.  Full Article

Synairgen says AstraZeneca decided to stop phase IIa AZD9412 trial
Wednesday, 12 Oct 2016 02:00am EDT 

Synairgen Plc : AZD9412 clinical trial update . Received Inexas clinical trial update from AstraZeneca relating to AZD9412 . AstraZeneca has decided to stop phase IIa trial for AZD9412 based on an interim analysis . interim analysis showed an overall very low number of reported severe exacerbations that could make primary endpoint conclusions difficult .AstraZeneca will evaluate key data collected from Inexas trial with a focus on secondary endpoints.  Full Article

Insmed announces worldwide license agreement with AstraZeneca for oral DPP1 inhibitor
Wednesday, 5 Oct 2016 06:55am EDT 

Insmed Inc : Insmed will pay AstraZeneca an upfront payment of $30 million . Agreement provides AstraZeneca with option to negotiate a future agreement with Insmed for commercialization of AZD7986/ins1007 . Continue to expect patient enrollment in phase 3 study of Arikayce to conclude later this year and to report top line data in 2017 . Confirms its cash operating expense guidance for second half of 2016 of $62 million to $72 million . In a phase 1 study of healthy volunteers AZD7986 was well tolerated . Says AstraZeneca will be eligible to receive future payments totaling $120 mln in future clinical, regulatory, and sales-related milestones .Confirms its cash operating expense guidance for second half of 2016 of $62 to $72 million..  Full Article

Allergan Plc enters licensing agreement with Astrazeneca for worldwide rights to Medi2070
Monday, 3 Oct 2016 02:00am EDT 

Allergan Plc : In addition, Allergan may make potential payments to astrazeneca of up to $1.27 billion, payable over a period of up to 15 years . Says Medimmune will continue ongoing medi2070 phase iia study in crohn's disease to completion . Potential payments include launch milestone payments of up to $435 million and sales-based milestone payments of $725 million . Allergan plc enters into licensing agreement with astrazeneca to obtain worldwide rights to medi2070 inflammatory disorder development program . Allergan will make an upfront payment to astrazeneca of $250 million for exclusive, worldwide license to develop and commercialize medi2070 .Says medimmune will transition phase IIb study in crohn's disease to allergan for completion.  Full Article

FDA approves Astrazeneca's blood-based companion diagnostic for Tagrisso (osimertinib)
Thursday, 29 Sep 2016 07:25am EDT 

Astrazeneca Plc :U.S. FDA has approved a blood-based companion diagnostic for Tagrisso (osimertinib).  Full Article

Astrazeneca says asthma drug shows positive results in phase III trials
Monday, 5 Sep 2016 01:05am EDT 

Astrazeneca Plc : Benralizumab phase III trials show positive results in severe asthma .Respiratory medicine met primary and secondary endpoints in trials for severe asthmaresults from pivotal phase iii trials presented at European Respiratory Society International Congress.  Full Article

More From Around the Web


GSK and Regeneron to mine gene data from 500,000 Britons

LONDON Britain's GlaxoSmithKline and U.S.-based Regeneron Pharmaceuticals are embarking on a joint project with UK Biobank, the world's most detailed biomedical database, to hunt for new clues linking genes and disease.